Inhibikase Therapeutics Inc. (IKT) News

Inhibikase Therapeutics Inc. (IKT): $0.76

0.02 (+2.34%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add IKT to Watchlist
Sign Up

Industry: Biotech


Ranked

of 465

in industry

Filter IKT News Items

IKT News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest IKT News From Around the Web

Below are the latest news stories about Inhibikase Therapeutics Inc that investors may wish to consider to help them evaluate IKT as an investment opportunity.

Parkinson''s Disease Pipeline Offers Promising New Options for Treatment | DelveInsight

Los Angeles, USA, Jan. 17, 2022 (GLOBE NEWSWIRE) -- Parkinson''s Disease Pipeline Offers Promising New Options for Treatment | DelveInsight DelveInsight''s "Parkinson''s Disease Pipeline Insight" report provides comprehensive insights about 150+ companies and 150+ pipeline drugs in the Parkinson''s Disease pipeline landscapes. The report comprises Parkinson''s Disease pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Parkinson''s Disease therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Parkinson''s Disease pipeline products. Some of the key takeaways from the Parkinson''s Disease Pipeline Report Major Parkinson''s Disease companies such as Cerevel Therapeutics, Ab...

Benzinga | January 17, 2022

Inhibikase Therapeutics Highlights 2022 Pipeline Goals and Milestones

Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson's disease and related disorders, today highlighted recent developments and anticipated milestones for 2022.

Yahoo | January 5, 2022

Reviewing Genocea Biosciences (NASDAQ:GNCA) and Inhibikase Therapeutics (NYSE:IKT)

Inhibikase Therapeutics (NYSE:IKT) and Genocea Biosciences (NASDAQ:GNCA) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, earnings, profitability, risk, analyst recommendations, valuation and dividends. Analyst Recommendations This is a summary of recent ratings and price targets for Inhibikase Therapeutics []

Dakota Financial News | December 20, 2021

Contrasting Inhibikase Therapeutics (IKT) & Its Competitors

Inhibikase Therapeutics (NYSE: IKT) is one of 237 publicly-traded companies in the Biological products, except diagnostic industry, but how does it compare to its rivals? We will compare Inhibikase Therapeutics to related companies based on the strength of its valuation, risk, earnings, profitability, analyst recommendations, dividends and institutional ownership. Valuation & Earnings This table compares []

Dakota Financial News | December 5, 2021

Inhibikase Therapeutics Inc. (NASDAQ:IKT) Has Recovered -2.42% So Far, But Another -627.27% Loss Cannot Be Ruled Out

In last trading session, Inhibikase Therapeutics Inc. (NASDAQ:IKT) saw 0.55 million shares changing hands with its beta currently measuring 0. Companys recent per share price level of $1.65 trading at -$0.12 or -6.78% at ring of the bell on the day assigns it a market valuation of $41.25M. That closing price of IKTs stock is Inhibikase Therapeutics Inc. (NASDAQ:IKT) Has Recovered -2.42% So Far, But Another -627.27% Loss Cannot Be Ruled Out Read More »

Marketing Sentinel | December 4, 2021

Inhibikase Therapeutics Announces Publication Highlighting Mechanism of Disease and the Potential of Oral c-Abl Kinase Inhibitor Therapy for the Treatment of Parkinson's Disease

Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson's disease and related disorders, today announced the publication of a paper describing the biochemical rationale and potential benefit of Abelson Tyrosine Kinase (c-Abl) inhibition as a potential disease-modifying therapy for Parkinson's Disease. The article, titled "Parkinson's Disease Modification Through Abl Kinase Inhibitio

Yahoo | November 29, 2021

Analysts Offer Insights on Healthcare Companies: Inhibikase Therapeutics (IKT) and Mustang Bio (MBIO)

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Inhibikase Therapeutics (IKT – Research Report) and Mustang Bio (MBIO – Research Report) with bullish sentiments. Inhibikase Therapeutics (IKT) In a report issued on November 17, Soumit Roy from JonesTrading maintained a Buy rating on Inhibikase Therapeutics, with a price target of $12.00. The company's shares closed last Friday at $1.90, close to its 52-week low of $1.72. According to TipRanks.

Howard Kim on TipRanks | November 22, 2021

Inhibikase Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Recent Period Activity

Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson's disease and related disorders, today reported financial results for the third quarter ended September 30, 2021 and highlighted recent developments.

Yahoo | November 15, 2021

Inhibikase Therapeutics to Participate in Upcoming Michael J. Fox Foundation Alpha-Synuclein Summit

Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson's disease and related disorders, today announced that Dr. Milton Werner, Ph.D., President & Chief Executive Officer of Inhibikase, will participate in the Michael J. Fox Foundation Alpha-Synuclein Summit being held virtually from November 3-4, 2021.

Yahoo | October 27, 2021

Inhibikase Therapeutics Announces Dosing of First Parkinson's Patient in its Phase 1b Clinical Trial of IkT-148009

Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson's disease and related disorders, today announced dosing of the first Parkinson's patient in its Phase 1b clinical trial of IkT-148009, an Abelson Tyrosine Kinase, or c-Abl, inhibitor for the treatment of Parkinson's disease.

Yahoo | October 19, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5416 seconds.